|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3 Suppl 6
|
|
pubmed:dateCreated |
1996-8-15
|
|
pubmed:abstractText |
Two studies were performed to determine the maximum tolerated dose (MTD) of paclitaxel and vinorelbine, respectively, in combination with a fixed dose of ifosfamide in previously untreated patients with stage IIIB or IV non-small cell lung cancer. Response rate and survival were also assessed. Both regimens were given with mesna and granulocyte colony-stimulating factor support. The maximum tolerated dose of paclitaxel in combination with 1.6 g/m2/d X 3 ifosfamide was 300 mg/m2, and the recommended dose for phase II study is 250 mg/m2. Among 31 patients treated with ifosfamide/paclitaxel, there were seven partial responses; additionally, 10 patients had either minor regression or stable disease. The maximum tolerated dose of vinorelbine in combination with 1.6 g/m2/d X 3 ifosfamide was 35 mg/m2/d X 3, and the recommended dose for phase II study is 30 mg/m2/d X 3. Among 42 patients treated with ifosfamide/vinorelbine, responses have been encouraging, and final analysis is pending. The dose-limiting toxicity for both regimens was neutropenia. These findings indicate that ifosfamide-containing combination chemotherapy regimens have activity in advanced non-small cell lung cancer and are well tolerated when administered with granulocyte colony-stimulating factor.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Alkylating,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic,
http://linkedlifedata.com/resource/pubmed/chemical/Expectorants,
http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte Colony-Stimulating...,
http://linkedlifedata.com/resource/pubmed/chemical/Ifosfamide,
http://linkedlifedata.com/resource/pubmed/chemical/Mesna,
http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel,
http://linkedlifedata.com/resource/pubmed/chemical/Vinblastine,
http://linkedlifedata.com/resource/pubmed/chemical/vinorelbine
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0093-7754
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
11-5
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:8677441-Adult,
pubmed-meshheading:8677441-Aged,
pubmed-meshheading:8677441-Antineoplastic Agents, Alkylating,
pubmed-meshheading:8677441-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:8677441-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8677441-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:8677441-Drug Tolerance,
pubmed-meshheading:8677441-Expectorants,
pubmed-meshheading:8677441-Female,
pubmed-meshheading:8677441-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:8677441-Humans,
pubmed-meshheading:8677441-Ifosfamide,
pubmed-meshheading:8677441-Lung Neoplasms,
pubmed-meshheading:8677441-Male,
pubmed-meshheading:8677441-Mesna,
pubmed-meshheading:8677441-Middle Aged,
pubmed-meshheading:8677441-Neoplasm Staging,
pubmed-meshheading:8677441-Neutropenia,
pubmed-meshheading:8677441-Paclitaxel,
pubmed-meshheading:8677441-Remission Induction,
pubmed-meshheading:8677441-Survival Rate,
pubmed-meshheading:8677441-Vinblastine
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Ifosfamide-based combination chemotherapy in advanced non-small cell lung cancer: two phase I studies.
|
|
pubmed:affiliation |
Department of Medicine, The University of Chicago, Louis A. Weiss Memorial Hospital, IL 60637, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study,
Clinical Trial, Phase I
|
